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Introduction 
Respiratory muscles (RM) have the structural, 
physiological and biochemical characteristics of skel- 
etal muscles. The only difference is that the RM 
contract continuously and breathing is a lifetime 
endurance task. Impairment of RM function by 
myopathy, neuropathy or both, puts life in great 
danger. The physiological function of the RM, like 
that of all skeletal muscles, is a multifactorial, compli- 
cated procedure. It requires not only the structural 
integrity of the muscles, their neurons and neuromus- 
cular junction, but also, among others, an adequate 
energy supply, normal metabolism with intact intra- 
cellular biochemical pathways as well as a balance of 
extra-and intra-cellular electrolytes. It is well known 
that a number of the above functions are regulated 
and/or affected by hormones. Therefore, it is not sur- 
prising that a variety of endocrinopathies are associ- 
ated with skeletal myopathies. Recently evidence 
has accumulated showing that RM function is also 
impaired in hormonal disturbances. In this paper we 
will review this evidence but first we will discuss in brief 
muscle contraction and identify potential mechanisms 
that could be affected by hormones. Secondly, we will 
discuss RM function in each endocrinopathy and 
finally we will propose areas for further investigation. 
Theoretical Aspects 
Skeletal muscles contain about 80% water and the 
remaining 20% consists mainly of proteins (I). The 
basic muscle proteins are the pairs of myosin/actin 
and tropomyosin/troponin. According to the sliding 
filament theory (2,3), in a resting state, the myosin 
head contains adenosinediphosphate and inorganic 
phosphate (ADP+Pi) and tropomyosin which pre- 
vents the combination of myosin to actin. During 
muscle activation there is a release of Ca2+causing 
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the myosin’s head to bind with actin and ADP + Pi to 
dissociate from the actomyosin complex. This results 
in movement of the thin filament towards the center 
of the sarcomere thus producing a working stroke, in 
other words the shortening of the muscle. Next, ATP is 
taken up and dissociates actin from myosin. The ATP 
is then hydrolysed and the products ADP, Pi remain in 
the myosin ready for the next stroke. This procedure 
continues until Ca’+is removed to troponin and relax- 
ation occurs. Thus, muscle energy utilization (ATP) is 
related to mechanical work (stroke). 
It is obvious that the high energy phosphate (ATP) 
is the primary fuel for muscle contraction (4). ATP 
is restored at the expense of creatine kinase (PCr) 
which is plentiful and active. This reaction is affected 
by Mg2+. PCr stores are replenished by glycolysis 
and oxidative phosphorylation (5). In anaerobic con- 
ditions, the breakdown of glycogen towards lactic acid 
forms 3 ATP molecules. In contrast, in the presence of 
oxygen, one glycogen molecule produces 36 ATP mol- 
ecules and no lactic acid. The above chemical reactions 
are complicated, form pathways, and a number of 
enzymes and ions are responsible for intermediate 
steps. 
Facilitation of glucose transport across the plasma 
membrane is observed in active muscles, but first the 
active muscle utilizes intracellular glycogen which is 
stored in forms of granules. Thus, the first step in 
energy supply to the muscle is glycogenolysis. Phos- 
phorylase is the enzyme responsible for glycogenolysis 
and is activated by Ca2+ release from the sarco- 
plasmic reticulum, by adrenalin and other circulating 
hormones. The regulation of glycolysis during acti- 
vation of muscles is not clearly understood but it has 
been shown that it is closely related to the contraction 
itself (6,7). 
RMs, like all skeletal muscles, have to be excited 
in order to contract. The excitation comes from the 
motor neurons and crosses towards the muscles at 
the neuromuscularjunction. Acetylcholine (Ach) is the 
chemical neurotransmitter substance which when it is 
released from the nerve ending, binds to specific ACh 
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Table I Possible pathophysiological mechanisms of the action of various hormones on the 
respiratory muscles 
Hormone Contractility 
Energy/ 
metabolism 
Membrane 
permeability 
Protein 
turnover 
Growth hormone 
Antidiuretic hormone 
Thyroid hormones 
Parathyroid hormone 
Corticosteroids 
Aldosterone 
Testosterone androgens 
Adrenaline 
Noradrenaline 
Insuline 
? + 
? ? 
+ + + + 
+ + 
+ + + + 
+ + 
+ ? + 
+ + + + 
+ + 
+ + ? + 
receptors at the outer of the postsynaptic membrane 
(muscle side). This reaction opens ionic channels and 
allows Na+, Ca*+ and K+ to pass, causing depolariz- 
ation of the membrane (8). Then an action potential is 
triggered and moves downward in the muscle fibres. 
ACh is rapidly hydrolysed by acetylcholinesterase 
(AChE) and is thus available for the next nerve 
impulse. Choline is the precursor of ACh and Na+ and 
Cl- affect this metabolic pathway. Ca*+, Mg2+ and 
other electrolytes are involved in the storage, or the 
releasing processes of ACh (9). 
The conduction of the action potential (excitation) is 
along the surface of the sarcolemma and via the sarco- 
tubular system of the muscle. This T-tubular system 
serves to bring excitation deep into the fibre interior 
very rapidly. The procedure is Na+-dependent. What 
follows is called the excitation -contraction coupling 
(E-C). Lately it has been established that the main 
process in E-C is that of the Ca*+ release from the 
sarcoplasmic reticulum, which occurs between the 
depolarization of the T-tubules and the development 
of tension. Critical concentrations of other electro- 
lytes, e.g. K+, Mg*+ are also important for the E-C 
coupling process. Finally, Ca*+ activates the thin fila- 
ment of myosin and a muscle stroke begins. Although, 
the mechanism of E-C coupling is not clearly under- 
stood, the integrity of the Na-K pump, the Ca-pump 
and the so called Ca-Na exchange system of the fibres 
arevital(lO-21). 
Mechanisms of the Action of Hormones on Respiratory 
Muscle Function 
The foregoing brief discussion has indicated that 
a number of possible mechanisms of action could 
explain the effect of hormonal dysfunction on the RM. 
However, the main pathophysiological mechanisms 
by which endocrinopathies affect RM function are 
four: 1, altering contractility (22-28); 2, altering energy 
supply and metabolic pathways (29-33); 3, altering 
membrane permeability (34,35) and 4, altering protein 
turnover (3643). Table 1 summarizes the mode of 
action of various hormones on the muscles. It can be 
seen that hormones could affect muscle function by a 
combination of different mechanisms. 
PITUITARY DYSFUNCTION 
Acromegaly 
A number of abnormalities of the respiratory system 
were reported in patients with excess production of 
growth hormone in adult life. These reports included 
early death due to respiratory disease (44), narrowing 
of the extrathoracic airways (45), sleep apnoea syn- 
drome (46) large lung volumes (47) and abnormal 
function of small airways (48). The few available 
reports on values of maximum pressures in acromegaly 
(49) suggest that RM function is normal but it is worth 
investigating RM in a larger number of patients. 
Hypopituitarism 
In patients with a deficiency of growth hormone in 
adult life, small lung volumes have been reported by 
Jain et al. (50). In addition, they showed that RM 
strength was normal in all 12 patients with long stand- 
ing growth hormone deficiency. Similar results were 
reported by De Troyer et al. (51). The authors found 
normal inspiratory muscle strength in four patients 
and concluded that muscle weakness was not the cause 
of small TLC. Since these studies were performed in a 
small number of patients, further studies are needed to 
clarify RM function in pituitary dysfunction. 
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Diabetes Insipidus 
Antidiuretic hormone (ADH) is produced in the 
posterior pituitary and exhibits vasopressor and 
plasma osmolality control. Diabetes insipidus, the 
disease due to insufficient ADH, is characterized by 
polyuria, hypertonicity and hypernatremia. These 
could potentially alter RM function but no relevant 
study was found in the available literature. 
THYROID GLAND 
Histopathological studies 
In skeletal muscles thyroid hormones have been 
shown to alter the speed of contraction/relaxation (25) 
or Ca’+ pump function (26). In addition thyroid 
hormones stimulate metabolism, membrane depolariz- 
ation and myosin ATPase, and influence protein turn- 
over (32,33,40). Experimental studies in rats showed 
that hypothyroidism increased the proportion of type 1 
slow oxidative fibres of the diaphragm and hyperthy- 
roidism decreased type 1 fibres (52). Ianuzzo et al. (53) 
showed an overall modification of enzymatic capacity 
of the diaphragm (i.e. glycolysis, tricarboxylic acid 
cycle, fatty acid oxidation) along with the proportion 
of alkali-liable to alkali-stable fibre types. 
Hyperthyroidism (thyrotoxicosis) 
It it well known that skeletal muscle weakness is 
a very common symptom in thyrotoxicosis. It was 
shown by Ramsay that 82% of hyperthyroid patients 
suffer from skeletal muscle weakness and when electro- 
myographic techniques were applied 93% of the 
patients showed evidences of myopathy (54). Although 
as early as 1917 it was demonstrated that the respir- 
atory system was affected in hyperthyroidism (55), it 
was only recently, that attention was paid to the 
function of the RM. 
In 1961 Stein et al. first reported that RM strength 
was reduced in hyperthyroidism (56). These investi- 
gators measured maximal expiratory and inspiratory 
mouth pressures and found them reduced. They con- 
cluded that these results are evidence of RM weakness. 
Later in 1978, Freedman, found small and inconsistent 
changes in maximal respiratory pressures in six thyro- 
toxic patients (57). In order to verify these dis- 
crepancies Siafakas et al. (58) measured maximum 
inspiratory and expiratory pressures in a larger group 
of hyperthyroid patients and found that indeed the 
pressures were reduced. The authors concluded that 
both respiratory muscle groups are weak in hyper- 
thyroidism and that the weakness was reversible by 
medical treatment. Similar findings were reported by 
Miers et al. in seven patients with hyperthyroidism 
complaining of dyspnoea (59). These investigators 
measured muscle strength as well as transdiaphrag- 
matic pressure (Pdi) during sniff and bilateral phrenic 
nerve stimulation. They concluded that there is RM 
weakness in thyrotoxicosis. In an effort to relate RM 
function and breathlessness in thyrotoxic patients 
McElvaney et al. (60) studied maximal static respirat- 
ory pressures, dyspnoea index and exercise parameters 
in 12 patients. Although they found that maximal 
pressures were reduced and improved after treatment 
they failed to show any difference in breathlessness 
intensity scores between patients and matched con- 
trols or a relationship between pressures and thyroid 
function. 
However, recently Siafakas et al. (61) studied 20 
consecutive hyperthyroid patients and showed not 
only that RM were weak but that this weakness was 
proportional to the degree of thyroid dysfunction. The 
investigators found a linear relationship between both 
maximal pressures (insp-exp), triiodothyronine and 
thyroxine blood levels. They concluded that these 
results are of clinical importance, since RM weakness 
is a common finding in thyrotoxicosis and it may cause 
respiratory failure (pump failure) in the more severe 
cases. 
Hypothyroidism (myxedema) 
In 1960 Wilson and Bedell investigated the pulmon- 
ary abnormalities in myxedema (62). They showed 
that maximal breathing capacity was reduced but 
increased significantly after therapy. They suspected 
that the RM or the neuromuscular coordination were 
involved. Freedman, in 1978, studied three hypothy- 
roid patients and reported that one had reduced VC 
attributable to the decrease of inspiratory muscle 
force (57). Later, in 1986 and 1987, it was reported by 
Ashtyani et al. (63) and Siafakas et al. (64) that global 
RM strength was low in hypothyroidism. In 1988, 
Laroche et al. (65) by measuring maximal pressures, 
Pdi and sniff Pdi described a patient with hypothy- 
roidism and respiratory muscle weakness and/or 
phrenic nerve neuropathy reversible with treatment. 
Three patients with hypothyroidism and chronic 
alveolar hypoventilation were studied by Martinez et 
al. (66) and found to have reversible diaphragmatic 
dysfunction. In a large series of 43 hypothyroid 
patients Siafakas et al. (67) investigated respiratory 
muscle strength before and three months after replace- 
ment therapy. They showed that mild RM weakness is 
a command finding in hypothyroidism and that this 
weakness is proportional to the degree of thyroid 
dysfunction. RM weakness was present in both 
long-standing and short-duration hypothyroidism (4 
weeks) and RM strength improved after therapy. They 
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concluded that thyroid dysfunction must be included 
in the differential diagnosis of unexplained respiratory 
failure requiring mechanical ventilation (67). 
Although the above studies on hyper/hypothy- 
roidism clearly demonstrate that RM weakness is pres- 
ent in thyroid diseases, the exact mechanism is obscure. 
Therefore, new studies are needed in humans, includ- 
ing RM biopsies and histopathological/enzymatic 
analyses. 
PARATHYROID GLANDS 
It is well known that parathyroid hormone regulates 
Ca*+ levels in the blood. Since Ca*+ is the vital sub- 
stance of the neuromuscular function it is apparent 
that parathyroid gland disturbances will be manifested 
by muscle dysfunction. 
Hypoparathyroidism 
It causes not only hypocalcemia but also hyper- 
phosphatemia and that leads to neuromuscular irrita- 
bility, paraesthesias, muscle cramps and tetany. Baker 
et al. reported the case of a child suffering from 
hypoparathyroidism and synchronous diaphragmatic 
flutter (68). 
Hyperparathyroidism 
Hyperparathyroidism on the other hand, increases 
blood Ca*+ and reduces pH, and in the majority of 
cases it is accompanied by proximal muscle weakness, 
malaise and fatigability. In 1987, Gomez-Fernadez 
et al. (69) reported an uremic patient on dialysis with 
severe, secondary hyperparathyroidism, proximal 
muscle weakness and impaired RM strength. Marked 
improvement in RM function was observed after sub- 
total parathyroidectomy. Kristoffersson et al. (70) 
studies RM in ten hyperparathyroid patients by 
measuring maximal pressures (Ptmax, Pnmax). They 
reported that only PEmax was improved significantly 
612 months after surgery. mmax was unchanged. The 
authors gave no explanation for this discrepancy. It is 
obvious that further studies are required to investigate 
RM function in parathyhroid diseases in humans. 
Furthermore, the effect of hypophosphatemia on 
diaphragmatic contractility was studied in dogs by 
Planas et al. (71) and in patients with acute respiratory 
failure by Aubier et al. (72). Both studies supported 
that hypophosphataemia impairs the contractile 
properties of the diaphragm. 
THE ADRENALS 
The adrenal glands are essential to life and produce 
a number of vital hormones. Among these hormones 
are corticosteroids, aldosterone, androgens and 
catecholamines. 
Adrenal cortex 
Glucocorticosteroids. Steroids have multiple influ- 
ences on the intermediary metabolism of cells. In brief, 
steroids affect glucose uptake by tissues and the pro- 
cess of gluconeogenesis; they block the synthesis of 
protein and nucleic acid and thus increase their turn- 
over, and in addition can produce hyperlipidemia. 
Therefore, glucocorticosteroids affect muscle function 
by altering energy supplies, metabolism and protein 
turnover. In addition, steroids affect Ca2+ metabolism 
and infuence the effect of other hormones, such 
as insulin and parathormones. Furthermore, gluco- 
corticosteroids are synergistic with adrenaline and 
glucagon in stimulating gluconeogensis. 
However, most of the evidence concerning the effect 
of steroids on muscle structure and function are from 
the administration of these hormones in experimental 
studies or are due to iatrogenic effects. A number of 
animal studies have shown that there are a variety of 
histological/functional changes in the skeletal as well 
as the RM after chronic or acute administration of 
corticosteroids (73-77). Diaphragmatic weight loss, of 
approximately 30%, was a common finding in the 
above reports (73-77). Vacuolization, fragmentation 
and rhabdomyolysis were also common but inter- 
species variations were noted. In addition, histological 
and biochemical studies showed that there are also 
fibre-type changes and/or enzymatic alterations of the 
RM during steroid induced myopathy. In summary, 
acute steroid induced myopathy involves the RM, 
which exhibit atrophy and rhabdomyolysis. Chronic 
myopathy produces selective fibre-type atrophy, alter- 
ation in contractile properties and other biochemical 
and functional changes in the diaphragm. These find- 
ings were more profound when fluorinated steroids 
were used. A recent review on the subject has been 
published by Dekhuijzen and Decramer (80). In 
humans there are only a few studies which investigate 
the effect of the administration of steroids on RM 
function. Bowyer et al., in 1985, reported that Ptmax 
correlated with hip flexor strength in steroid depen- 
dent asthmatic patients (81). Picado et al. (82) studied 
steroid dependent (12 mg day-‘) and non-steroid 
dependent asthmatic subjects and found that maximal 
respiratory pressures (PImax Pamax) and the strength 
of the deltoid were not significantly different between 
the two groups. Janssen and Decramer reported two 
patients with collagen vascular disorders who 
showed clinical improvement and marked increase in 
maximal respiratory pressures after gradual steroid 
tapering (83). 
Patients with COPD on steroids showed a corre- 
lation between daily steroid dose and RM strength. 
Recently two patients with asthma and one with 
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COPD on methylprednisone, who developed RM 
myopathy, were described (84). However, the results 
of the above studies have to be read with caution since 
the underlying disease could influence the RM mech- 
anic due to hyperinflation or due to myopathy itself 
(collagen disease). 
In addition, Wang et al. (85) showed that 20 mg of 
prednisone for 2 weeks had no effect on Ptmax, 
Pamax, Pdi,,, or RM endurance in normal subjects. 
Cushing’s disease. Cushing’s disease is the endo- 
crinopathy characterized by high blood levels of 
corticosteroids. The disease presents with weakness 
and proximal skeletal myopathy in 80-100% of cases. 
Although myopathy is very common in Cushing’s dis- 
ease we are not aware of studies investigating RM 
function in this illness. Therefore, such studies are 
needed. 
Mineralocorticoids. Aldosterone is responsible for 
sodium (Na+) ion reabsorption and potassium (K+) 
ion secretion from the kidneys. Thus, an excess of 
mineralocorticoids results in hypernatraemia, hypo- 
kalaemia and alkalosis. In contrast, pure minero- 
corticoid deficiency is related to hyponatraemia, 
hyperkalaemia and acidosis. Both Na+and K+ are 
vital electrolytes for muscle contraction and aldoster- 
one dysfunction is related to skeletal muscle weakness 
(86). Hyperkalaemia, in the hypo-aldosteronic state, 
can be the cause of secondary periodic paralysis. 
In primary adrenocortical insufficiency (Addison’s 
disease) glycocorticoids and mineralocorticoids are 
deficient and muscle fatigue and weakness are very 
common. However, only Mier et al. (87), in 1988, 
reported a case of Adisson’s disease presenting with 
dyspnoea on exertion that was related to severe RM 
weakness. RM function returned to within the normal 
range after treatment. 
Adrenal androgens. These hormones, as well as 
testosterone and estrogen, alter protein synthesis and 
express their androgen action by mild Na+ retention 
and protein anabolism. Competitive athletes use 
androgenic anabolic steroids to improve endurance 
strength and performance of skeletal muscles but the 
results are dubious. However, no report was found 
which investigated in particular the RM function of 
such athletes. 
Adrenal medulla 
This part of the adrenal glands produces the 
catecholamines (noradrenaline and adrenaline). Cat- 
echolamines, as shown in Table 1, influence muscle 
function by altering contractility, energy supply and 
metabolism(glycogenolysis-inducedinsulinsecretion), 
prolongation of action potential of the membrane and 
protein turnover. The effects of catecholamines and 
their derivatives (B2 adrenergics) on diaphragmatic 
contraction have not been studied extensively in vivo. 
However, early studies showed that these hormones 
when administered could affect diaphragmatic func- 
tion by producing an abundance of /I receptors, alter- 
ation of metabolic activity and potentiation of twitch 
response in vitro. More recently, it has been shown 
that isoprenaline improves the contractility of a 
fatigued diaphragm in dogs by approximately 10%. 
Terbulatine is a &adrenergic proved to have no effect 
on a fresh diaphragm preparation but did have an 
important positive (isotropic) effect on the fatigued 
diaphragm (88). Clearly more studies in vivo and in 
humans are needed to elucidate the role of sympatho- 
mimetic hormones and their derivatives on the RMs. 
In diseases of the adrenal medulla, such as pheo- 
chromocytoma (excess of catecholamine production) 
or adrenaline deficiency, RM function has not been 
studied presumably because these conditions are rare. 
DIABETES MELLITUS 
Insulin regulates blood glucose, its uptake by 
various tissues, and has been also shown to induce 
hyperpolarization of the muscle membrane by increas- 
ing K+ uptake in exchange with H+. Furthermore, 
a number of biochemical/enzymatic and functional 
changes of skeletal muscles in diabetes mellitus have 
been reported in the literature. Cameron et al. showed 
that polyol pathway activity was an important factor, 
probably through the disruption of Ca*+-handling, 
explaining functional changes of skeletal muscles in 
diabetes (89). Borsey et al. reported atrophic manifes- 
tations in the small hand muscles of diabetic patients 
related to autonomic nerve dysfunction (90). In ad- 
dition, reduction of glucose transporters in the muscles 
could cause impaired glucose utilization in diabetes. 
Recently in experimentally-induced diabetes in ani- 
mals it was shown that diaphragmatic neuromyopathy 
appears to be a state of abnormal Ca*+ mobilization 
secondary to high levels of blood glucose (91). In 
addition, Nakagawa et aI. (92) showed that the dia- 
phragms of diabetic mice were atrophic, with dis- 
appearance of the 2-band, disturbed myofibrils and 
swollen sarcoplasmic reticulum. Furthermore, the 
investigators found changes in metal content (Ca’+, 
Mg2+, Fe+, Zn+)of various muscles including the 
diaphragm and concluded that the changes induced by 
the diabetic state may be related to the morphological 
abnormalities (92). 
However, only a few studies have addressed the 
issue of RM performance in human diabetic patients. 
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In 1990, Heimer et al. (93) investigated RM strength 
and endurance as well as lung volume and maximum 
voluntary ventilation (MVV) in 31 type 1 diabetic 
patients. The authors reported that no difference was 
noted in Prmax and PEmax between the diabetic 
patients and a group of matched subjects. Only RM 
endurance was lower in diabetics. In addition, they 
reported that TLC and VC as well as MVV were lower 
in diabetics and correlated with the duration of the 
disease. Wanke et al. (94), in 1991, studied inspiratory 
muscle function in 36 patients with insulin-dependent 
diabetes. They measured sniff Pdi and Pes, MVV, 
lung volumes and maximum expiratory flow-volume 
curves. In contrast to the results of Heimer (93), 
Wanke et al. (94) showed that inspiratory muscle 
performance was restricted in diabetics and both sniff 
Pdi and sniff Pes were lower than in normals. In 
addition, VC and MVV were also lower. However, 
they did not find a significant correlation between 
these volume parameters and the duration of the dis- 
ease. Wanke et al. concluded that the reduction in VC 
may have been caused partly by the reduced capacity 
of the inspiratory muscles (94). 
Furthermore, it was reported in case reports that 
diabetic ketoacidosis could cause hypokalaemic res- 
piratory arrest or hypophosphataemia and acute res- 
piratory failure (95). Thus, it is worth investigating 
RM function during diabetic ketoacidosis in order to 
prevent severe respiratory pump failure. In addition 
to the muscle dysfunction seen in diabetes, neural func- 
tion is also impaired and thus, the reflex mechanisms of 
the RM (95). 
Finally, the mechanisms of impairment of RM func- 
tion in diabetes mellitus could be due to myopathy, 
neuropathy or both but further investigation is required. 
Summary and Conclusions 
The aim of this review was to demonstrate that RM 
function is altered in various endocrinopathies and 
that RM weakness is a common finding. RM function 
has been well-studied in diseases such as thyroid dys- 
function, and steroid induced RM myopathies. Less 
well documented reports on RM function were found 
in parathyroid dysfunctions, disorders of mineralo- 
corticoids and pituitary disturbances. Controversial 
reports were found in diabetes mellitus. No report was 
found connecting RM function with androgens, pheo- 
chromocytoma or adrenaline deficiency in humans. 
These diseases could potentially cause RM impair- 
ment leading to severe respiratory failure (pump 
failure) putting life in great danger. 
Therefore, it is obvious that further studies are 
needed to investigate the performance of RMs in 
endocrinopathies. Such studies are extremely urgent 
in Cushing’s and Addison’s disease, acromegaly, 
disorders of the adrenal medulla, and in diabetes 
insipidus. 
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